{"id":53260,"date":"2023-09-20T09:44:26","date_gmt":"2023-09-20T09:44:26","guid":{"rendered":"https:\/\/medsname.com\/gefticip\/"},"modified":"2026-04-30T16:30:27","modified_gmt":"2026-04-30T16:30:27","slug":"gefticip","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/gefticip\/","title":{"rendered":"Gefticip"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<h3 style=\"margin-top:0;\">\u0393\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u03b1\u03c0\u03ac\u03bd\u03c4\u03b7\u03c3\u03b7<\/h3>\n<p style=\"margin-bottom:0;\"><strong>Gefticip<\/strong> \u2014 Gefitinib 250 mg (Cipla Inc). EGFR-TKI for EGFR-mutant non-small cell lung cancer.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f7f7f7;border-left:4px solid #2c7cb0;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0 0 6px 0;\"><strong>\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong><\/p>\n<ul style=\"margin:6px 0 0 22px;padding:0;list-style:disc;\">\n<li>\u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf \u03b1\u03c0\u03cc \u03c4\u03b7 WHO-GMP \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae<\/li>\n<li>\u03a3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u03c3\u03b5 \u03b1\u03c0\u03bb\u03cc \u03c6\u03ac\u03ba\u03b5\u03bb\u03bf \u03c7\u03c9\u03c1\u03af\u03c2 \u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/li>\n<li>\u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae<\/li>\n<li>\u0391\u03be\u03b9\u03bf\u03bb\u03bf\u03b3\u03ae\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc 1,400+ \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2 (<a href=\"https:\/\/medsbase.com\/el\/reviews\/\">\u03b4\u03b9\u03b1\u03b2\u03ac\u03c3\u03c4\u03b5 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2<\/a>)<\/li>\n<\/ul>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"background:#eef7ee;border-left:4px solid #4caf50;padding:10px 14px;margin:14px 0;border-radius:3px;\">\ud83d\udce6 <strong>\u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2:<\/strong> \u03b1\u03bd \u03b7 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03ad\u03c7\u03b5\u03b9 \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03bc\u03ad\u03c3\u03b1 \u03c3\u03b5 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03b5\u03c2 \u03b7\u03bc\u03ad\u03c1\u03b5\u03c2 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae, \u03c4\u03b7\u03bd \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5 \u03c7\u03c9\u03c1\u03af\u03c2 \u03c0\u03c1\u03cc\u03c3\u03b8\u03b5\u03c4\u03bf \u03ba\u03cc\u03c3\u03c4\u03bf\u03c2. <a href=\"https:\/\/medsbase.com\/el\/medsbase-re-shipment-assurance-policy\/\">\u0394\u03b9\u03b1\u03b2\u03ac\u03c3\u03c4\u03b5 \u03c4\u03b7\u03bd \u03c0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae<\/a>.<\/p>\n<h3>\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n<p>Gefticip ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor \u2014 never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.<\/p>\n<div class=\"medsbase-specialist-strip\" style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0;\"><strong>\u26a0\ufe0f Specialist-supervised cancer therapy<\/strong> \u2014 this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.<\/p>\n<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>TKI class principles<\/strong><br \/>Tyrosine kinase inhibitors are oral targeted therapies. They require specialist initiation, ongoing therapeutic drug monitoring (where available), and management of class-specific toxicities. Adherence is critical \u2014 missed doses risk treatment failure. Most TKIs are CYP3A4 substrates with major drug interactions.<\/div>\n<h2 id=\"faqs\">\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n<h3>What is a TKI?<\/h3>\n<p>Tyrosine kinase inhibitors block specific signalling pathways driving cancer cell growth. Each TKI is selective for different targets (EGFR for gefitinib\/erlotinib; multikinase for sorafenib\/sunitinib; BCR-ABL for nilotinib\/imatinib; BTK for ibrutinib; JAK for ruxolitinib; CDK4\/6 for palbociclib).<\/p>\n<h3>\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2;<\/h3>\n<p>Class signature: rash (often correlates with response in EGFR inhibitors), diarrhoea, fatigue, hand-foot skin reaction, hypertension (multikinase), hepatotoxicity, QT prolongation. Each TKI has a specific profile.<\/p>\n<h3>\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd;<\/h3>\n<p>Most TKIs are CYP3A4 substrates. Strong inhibitors (azoles, macrolides, ritonavir, grapefruit) raise levels and toxicity; strong inducers (rifampicin, phenytoin, carbamazepine, St John&#8217;s wort) drop levels and risk treatment failure.<\/p>\n<h3>Take with food?<\/h3>\n<p>Some TKIs (lapatinib, erlotinib) on empty stomach (food increases bioavailability variably). Others (gefitinib, sorafenib) with or without food. Specific instruction depends on the molecule \u2014 confirm with prescribing oncologist.<\/p>\n<h3>What about response monitoring?<\/h3>\n<p>Imaging (CT\/MRI\/PET) every 2-3 months early; tumour markers if applicable. Treatment continues while benefit; switch on progression or unacceptable toxicity.<\/p>\n<h3>\u0391\u03bd\u03c4\u03af\u03c3\u03c4\u03b1\u03c3\u03b7;<\/h3>\n<p>TKI resistance develops over time (typically 9-18 months in solid tumours). Mechanisms: target mutations (T790M for EGFR, T315I for BCR-ABL), alternate pathway activation, target overexpression. Next-generation TKIs (osimertinib, ponatinib) overcome specific resistance mutations.<\/p>\n<h3>\u03a4\u03b9 \u03b3\u03af\u03bd\u03b5\u03c4\u03b1\u03b9 \u03b1\u03bd \u03c7\u03ac\u03c3\u03c9 \u03bc\u03b9\u03b1 \u03b4\u03cc\u03c3\u03b7;<\/h3>\n<p>Take when you remember if same day if &gt;6 hours from next dose. Otherwise skip \u2014 do not double up. Specific instructions vary by drug; confirm with your oncology team.<\/p>\n<h3>\u0395\u03b3\u03ba\u03c5\u03bc\u03bf\u03c3\u03cd\u03bd\u03b7;<\/h3>\n<p>All TKIs are teratogenic \u2014 effective contraception during and for at least 4-6 months after for both partners.<\/p>\n<h3>Cardiac monitoring?<\/h3>\n<p>Multikinase TKIs (sorafenib, sunitinib): BP monitoring, ECG (QT), echocardiogram in selected cases. BCR-ABL TKIs (nilotinib): mandatory ECG at baseline and follow-up \u2014 QT prolongation.<\/p>\n<h3>Cost-effectiveness?<\/h3>\n<p>Generic TKIs are widely manufactured under voluntary licences in India and other jurisdictions. Indian generic prices are dramatically lower than branded equivalents. Quality and bioequivalence are well-documented.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Cancer Medications<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/xeloda\/\">Xeloda<\/a> \u2014 capecitabine 500 mg \u2014 oral 5-FU prodrug for breast\/colorectal\/gastric cancers<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/altraz\/\">Altraz<\/a> \u2014 anastrozole 1 mg \u2014 aromatase inhibitor for post-menopausal breast cancer<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/xbira\/\">Xbira<\/a> \u2014 abiraterone 250 mg \u2014 CYP17 inhibitor for metastatic prostate cancer<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/zoldria\/\">Zoldria<\/a> \u2014 zoledronic acid IV \u2014 for bone metastases and hypercalcaemia<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/actorise\/\">Actorise<\/a> \u2014 darbepoetin alfa \u2014 for chemotherapy-induced anaemia<\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:18px 0;border-radius:3px;font-size:.95em;\"><strong>\u0399\u03b1\u03c4\u03c1\u03b9\u03ba\u03ae \u0391\u03c0\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u0395\u03c5\u03b8\u03c5\u03bd\u03ce\u03bd:<\/strong> Cancer therapy is highly individualised. Specific drug, dose, schedule, monitoring, and supportive care must be determined by a qualified oncologist or haematologist based on tumour biology, staging, comorbidities, and goals of care. This information is educational; it does not substitute for professional medical advice.<\/div>","protected":false},"excerpt":{"rendered":"<p>Gefticip (Gefitinib 250 mg) \u2014 Cipla EGFR-TKI for EGFR-mutant non-small cell lung cancer. Once-daily oral targeted therapy.<\/p>","protected":false},"featured_media":53261,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223],"product_tag":[],"class_list":{"0":"post-53260","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","10":"first","11":"outofstock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/53260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=53260"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/53261"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=53260"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=53260"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=53260"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=53260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}